Compare KRG & GRFS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KRG | GRFS |
|---|---|---|
| Founded | 1971 | 1940 |
| Country | United States | Spain |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.2B | 6.2B |
| IPO Year | 2004 | 2006 |
| Metric | KRG | GRFS |
|---|---|---|
| Price | $24.32 | $9.53 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 9 | 2 |
| Target Price | ★ $25.33 | $10.15 |
| AVG Volume (30 Days) | ★ 2.0M | 452.1K |
| Earning Date | 02-10-2026 | 07-28-2022 |
| Dividend Yield | ★ 4.81% | 1.50% |
| EPS Growth | N/A | N/A |
| EPS | 0.64 | ★ 0.64 |
| Revenue | $856,786,000.00 | ★ $8,821,017,248.00 |
| Revenue This Year | $1.91 | $5.36 |
| Revenue Next Year | N/A | $5.15 |
| P/E Ratio | $37.97 | ★ $18.71 |
| Revenue Growth | 3.78 | ★ 7.31 |
| 52 Week Low | $18.52 | $6.19 |
| 52 Week High | $24.69 | $11.14 |
| Indicator | KRG | GRFS |
|---|---|---|
| Relative Strength Index (RSI) | 66.22 | 65.21 |
| Support Level | $23.36 | $9.17 |
| Resistance Level | $24.20 | $9.46 |
| Average True Range (ATR) | 0.32 | 0.19 |
| MACD | 0.00 | 0.04 |
| Stochastic Oscillator | 89.67 | 100.00 |
Kite Realty Group Trust specializes in owning, operating, acquiring, developing, and redeveloping high-quality open-air shopping centers and mixed-use assets. The company generates the majority of its revenue from contractual rents and reimbursement payments received from tenants.
Grifols SA one of is global specialty plasma therapeutics companies developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. Plasma derivatives are proteins found in human plasma, which once isolated and purified, have therapeutic value. These protein-based therapies extend and enhance the lives of individuals who suffer from chronic and acute, often life-threatening, conditions, including primary and secondary immunological deficiencies, Chronic Inflammatory Demyelinating Polyneuropathy, immune-mediated ITP. Products and services are used to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases and a range of other medical conditions. Majority of revenue is from USA.